Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Nasopharyngeal Carcinoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Sarcoma 2Respiratory Tract Diseases 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

Carboplatin 8Pemetrexed 5pembrolizumab 4osimertinib 3entinostat 3Paclitaxel 3Erlotinib Hydrochloride 3selpercatinib 2pralsetinib 2efatutazone 2durvalumab 2Gemcitabine 2Cisplatin 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1napabucasin 1ficlatuzumab 1exemestane 1cobimetinib 1ceralasertib 1camrelizumab 1alectinib 1aflutinib 1Patient Reported Outcome Measures 1Gefitinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Respiratory Tract Neoplasms × camrelizumab × Clear all
NCT03134872 2020-06-09

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
419 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡